Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

May 2023

Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)

Full data from first 100 patients at the one-year interim timepoint confirm significant and clinically important, sustained and gradually increasing efficacy on PANSS total, CGI-S and LOF

- 41 % of patients were much or very much improved (CGI-C)

- 29 % of patients showed improvement by 2 or 3 categories (CGI-S), compared to baseline

- 38% of patients qualified as “super-responders”

- PANSS total responders (> 20 % reduction compared to baseline) maintained their response

Final efficacy and safety results from all 161 patients at the six-week primary endpoint of Study 014 confirmed interim results and demonstrated improvement on all PANSS subscales, including negative symptoms

Results from this first international trial of an antipsychotic new chemical entity (NCE) as an add-on to a single antipsychotic in patients with TRS

- support movement to potentially pivotal, multinational, randomized, placebo-controlled trial

- suggest a potential new strategy for the management of TRS patients

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS) and based within OpenZone campus, presented substantial additional data from its study 014/015 at the 34th CINP World Congress of Neuropsychopharmacology from 7-10 May 2023 in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) from 11-15 May 2023 in Toronto, Ontario, Canada.

Study 014/015 is an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication.

The study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events. 97% of patients completed six weeks of treatment, and more than 90% of the completers chose to continue with evenamide treatment into the long-term extension study (study 015).

Final efficacy and safety results from all 161 patients at the six-week primary endpoint of Study 014 were announced in March 2023. Further data covering the improvement observed in all Positive and Negative Syndrome Scale (PANSS) subscales at six weeks, including negative symptoms, was presented at the CINP and SIRS Congresses.

Top-line one-year results from the first 100 patients in Study 014/015 were announced in February 2023 and showed a significant, clinically important and sustained improvement in symptoms, with a gradually increasing effect. Several posters were presented at the CINP and SIRS Congresses detailing the full results from this patient group.

Key findings and conclusions at twelve months:

  • Efficacy results based on changes from baseline in the PANSS, the Clinical Global Impression of Severity (CGI-S) as well as the Strauss Carpenter Levels of Functioning (LOF) showed a statistically significant improvement at 12 months (p-value < 0.001: paired t-test, LOCF). All efficacy scales showed gradual and sustained improvement during the same period
  • Increasing reduction in the PANSS total score was noted at all time-points compared to baseline; the PANSS responder rate (> 20% improvement) at 12 months was 47%, almost 3 three times the rate at week six (16%)
  • Ratings of the Clinical Global Impression of Change (CGI-C) indicated that 41% of the patients were rated as ‘much’ or ‘very much’ improved, versus baseline
  • The CGI-S improved (i.e. the disease severity was considered reduced) by 1.1 units from baseline. Importantly, 29% of patients experienced a two or three category improvement over baseline
  • 38% of patients qualified as “super-responders”, experiencing
    • A PANSS total score improvement of at least 20% and
    • an CGI-C of at least much improved and
    • an CGI-S of at least 1 point improvement and
    • an CGI-S of at most mildly ill
  • The proportion of patients considered as “super-responders” increased 2.5-fold from six weeks to one year
  • Patients who responded were more likely to complete the one-year treatment period than non-responders.
Ravi Anand
Chief Medical Officer at Newron


The results of study 014/015 presented at both the CINP and SIRS Congresses fully vindicate our extensive preclinical experiments, which indicated the benefits of adding evenamide to antipsychotics that were not efficacious in models of treatment resistance. The multi-modal-benefits observed across various domains with evenamide also validate extensive academic research, suggesting that TRS results from excessive glutamate signalling. Moreover, the gradual and continuous improvement in symptoms over time is unique to treatment with evenamide. We plan to initiate Study 003, a potentially pivotal, multinational, randomized, placebo-controlled trial in patients with TRS later this year and are confident that the results from that study will support the need for re-evaluation of the current therapeutic strategy for managing patients with TRS.